240 related articles for article (PubMed ID: 22812556)
1. When is switching warranted among biologic therapies in rheumatoid arthritis?
Reynolds A; Koenig AS; Bananis E; Singh A
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
[TBL] [Abstract][Full Text] [Related]
2. Perioperative management of biologic agents used in treatment of rheumatoid arthritis.
Mushtaq S; Goodman SM; Scanzello CR
Am J Ther; 2011 Sep; 18(5):426-34. PubMed ID: 20216205
[TBL] [Abstract][Full Text] [Related]
3. Drugs for rheumatoid arthritis.
Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
[No Abstract] [Full Text] [Related]
4. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
6. Malignancy and biologic therapy in rheumatoid arthritis.
Askling J; Bongartz T
Curr Opin Rheumatol; 2008 May; 20(3):334-9. PubMed ID: 18388527
[TBL] [Abstract][Full Text] [Related]
7. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
Hernández MV; Sanmartí R; Cañete JD
Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
[TBL] [Abstract][Full Text] [Related]
8. Management of rheumatoid arthritis.
Handa R
Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
[TBL] [Abstract][Full Text] [Related]
9. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
10. Abatacept as add-on therapy for rheumatoid arthritis.
Allison C
Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
[TBL] [Abstract][Full Text] [Related]
11. The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
Bansback NJ; Young A; Brennan A
Rheumatology (Oxford); 2005 Jan; 44(1):3-4. PubMed ID: 15328422
[No Abstract] [Full Text] [Related]
12. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
Mizutani W
Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
[TBL] [Abstract][Full Text] [Related]
13. Switching between anti-TNF-alpha agents does not improve functional capacity in patients with long-standing and active rheumatoid arthritis.
Soares MR; Reis Neto ET; Luz KR; Ciconelli RM; Pinheiro MM
Rev Bras Reumatol; 2012; 52(1):9-15. PubMed ID: 22286641
[TBL] [Abstract][Full Text] [Related]
14. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.
Keystone EC
J Rheumatol; 2011 Aug; 38(8):1552-62. PubMed ID: 21572154
[TBL] [Abstract][Full Text] [Related]
15. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
16. When to initiate and discontinue biologic treatments for rheumatoid arthritis?
Chatzidionysiou K; van Vollenhoven RF
J Intern Med; 2011 Jun; 269(6):614-25. PubMed ID: 21261760
[TBL] [Abstract][Full Text] [Related]
17. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
Park HJ; Ranganathan P
Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
[TBL] [Abstract][Full Text] [Related]
19. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review.
Sullivan SD; Alfonso-Cristancho R; Carlson J; Mallya U; Ringold S
J Med Econ; 2013; 16(3):391-6. PubMed ID: 23298329
[TBL] [Abstract][Full Text] [Related]
20. Infectious complications of biologic agents.
Martin-Mola E; Balsa A
Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
